InSync III Marquis Model 7279 Cardioverter Defibrillator Cardiac Resynchronization System
Launched by MEDTRONIC CARDIAC RHYTHM AND HEART FAILURE · Dec 28, 2005
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject has, or is at risk of having, a heart beat that is too fast and his/her doctor has determined the need for an implantable cardioverter defibrillator.
- • Subject is on optimal medical treatment for heart failure.
- • Subject has reduced left ventricular ejection fraction (LVEF≤35%). (LVEF is a measurement of how well the left ventricle pumps blood out to the rest of the body. The higher the LVEF the more blood the ventricle is pumping.)
- • Subject who has heart failure which severely limits daily activities (NYHA Class III) or subject who has severe heart failure and should always be resting (NYHA Class IV)
- • Subject who has a QRS≥130ms (The QRS interval is a measurement of how the electrical signal involved in a heart beat travels/conducts through the ventricles. A wide QRS (more than 120 ms) suggests that there is a conduction problem (or block) in the ventricles.)
- • Subjects with a left ventricular end diastolic dimension (LVEDD≥55mm). (The LVEDD is a measurement taken during an echocardiogram that is one indication of the health of the left ventricle.)
- Exclusion Criteria:
- • Subject has unstable chest pain, heart surgery within past 3 months
- • Subject has liver function tests greater than 3 times normal limits
- • Subject has chronic (permanent) atrial arrhythmias (fast heart beats in the upper chamber(s) of the heart)
About Medtronic Cardiac Rhythm And Heart Failure
Medtronic Cardiac Rhythm and Heart Failure is a leading division of Medtronic, dedicated to advancing innovative therapies for patients with cardiac rhythm disorders and heart failure. With a commitment to improving patient outcomes, this division focuses on developing cutting-edge medical devices and solutions that enhance the management of arrhythmias and heart failure. Leveraging extensive research and clinical expertise, Medtronic Cardiac Rhythm and Heart Failure aims to transform patient care through evidence-based approaches and a robust pipeline of groundbreaking technologies. Their work not only addresses immediate clinical challenges but also contributes to the long-term health and well-being of individuals with complex cardiac conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Jacksonville, Florida, United States
Atlanta, Georgia, United States
Kansas City, Missouri, United States
Anchorage, Alaska, United States
Tampa, Florida, United States
Kansas City, Kansas, United States
Rochester, New York, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Nashville, Tennessee, United States
Milwaukee, Wisconsin, United States
Minneapolis, Minnesota, United States
New York, New York, United States
Dallas, Texas, United States
Phoenix, Arizona, United States
Memphis, Tennessee, United States
Falls Church, Virginia, United States
Rochester, Minnesota, United States
Las Vegas, Nevada, United States
Lincoln, Nebraska, United States
Austin, Texas, United States
Stanford, California, United States
Cincinnati, Ohio, United States
Burlington, Massachusetts, United States
Syracuse, New York, United States
Columbia, Missouri, United States
Lebanon, New Hampshire, United States
Raleigh, North Carolina, United States
Pensacola, Florida, United States
Lancaster, Pennsylvania, United States
Wynnewood, Pennsylvania, United States
St. Paul, Minnesota, United States
Beech Grove, Indiana, United States
Aiken, South Carolina, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials